MAZE vs TMUS · rev $20.0M vs P/E 19, rev $22.79B
Maze Therapeutics, Inc. Common Stock (MAZE) versus T-Mobile US Inc (TMUS) — a side-by-side from cached financials, not a winner call.
Maze Therapeutics, Inc. Common Stock (MAZE) is a biotechnology company listed on US.
T-Mobile US Inc (TMUS) is a telecom services company listed on NASDAQ. It is led by Mike Sievert.
Latest reported MAZE revenue for 2026-06-30 was $20.0M. Net income was -$68.9M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. MAZE currently screens at market cap $525.3M.
Latest reported TMUS revenue for 2026-06-30 was $22.79B. Net income was $3.24B. Revenue was down 1.4% from 2026-03-31 to 2026-06-30. TMUS currently screens at market cap $196.21B and trailing P/E 19.3.
MAZE currently screens at market cap $525.3M. TMUS currently screens at market cap $196.21B and trailing P/E 19.3.
Not investment advice. Open the MAZE and TMUS stock pages for the full models.
Not investment advice.